These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19509486)

  • 21. Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
    Brugts JJ; Simoons ML
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1001-9. PubMed ID: 23030290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors.
    Chen YY; Liu D; Zhang P; Zhong JC; Zhang CJ; Wu SL; Zhang YQ; Liu GZ; He M; Jin LJ; Yu HM
    J Hum Hypertens; 2016 Dec; 30(12):766-771. PubMed ID: 27121444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular approaches to individualize antihypertensive drug therapy.
    Hiltunen TP; Kontula K
    Ann Med; 2012 Jun; 44 Suppl 1():S23-9. PubMed ID: 22713145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Individual sensitivity to antihypertensive drugs: genetic aspects].
    Minushkina LO; Zateĭshchikov DA; Sidorenko BA
    Kardiologiia; 2005; 45(7):58-65. PubMed ID: 16091664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine.
    Polimanti R; Iorio A; Piacentini S; Manfellotto D; Fuciarelli M
    Pharmacogenomics; 2014 Feb; 15(2):157-67. PubMed ID: 24444406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomics of Antihypertensive Drugs in Brazil: Recent Progress and Clinical Implications.
    Vecchia Genvigir FD; Dagli-Hernandez C; Hirata TDC; Zhou Y; Lauschke VM; Hirata MH; Hirata RDC
    Endocr Metab Immune Disord Drug Targets; 2022; 22(13):1263-1275. PubMed ID: 34951375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension in African Populations: Review and Computational Insights.
    Mabhida SE; Mashatola L; Kaur M; Sharma JR; Apalata T; Muhamed B; Benjeddou M; Johnson R
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33917487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in pharmacogenomics of drugs acting on hypertension.
    Trotta R; Donati MB; Iacoviello L
    Pharmacol Res; 2004 Apr; 49(4):351-6. PubMed ID: 15202514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension.
    Rahman F; Muthaiah N; Kumaramanickavel G
    Indian J Pharmacol; 2021; 53(4):301-309. PubMed ID: 34414909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
    Irvin MR; Lynch AI; Kabagambe EK; Tiwari HK; Barzilay JI; Eckfeldt JH; Boerwinkle E; Davis BR; Ford CE; Arnett DK
    J Hypertens; 2010 Oct; 28(10):2076-83. PubMed ID: 20577119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic information in the diagnosis and treatment of hypertension.
    Tomaszewski M; Zimmerli L; Charchar FJ; Dominiczak AF
    Curr Hypertens Rep; 2006 Aug; 8(4):309-16. PubMed ID: 16884662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics of hypertension and heart disease.
    Arwood MJ; Cavallari LH; Duarte JD
    Curr Hypertens Rep; 2015 Sep; 17(9):586. PubMed ID: 26272307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics of antihypertensive drugs: past, present and future.
    Johnson JA
    Pharmacogenomics; 2010 Apr; 11(4):487-91. PubMed ID: 20350127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
    Hiltunen TP; Donner KM; Sarin AP; Saarela J; Ripatti S; Chapman AB; Gums JG; Gong Y; Cooper-DeHoff RM; Frau F; Glorioso V; Zaninello R; Salvi E; Glorioso N; Boerwinkle E; Turner ST; Johnson JA; Kontula KK
    J Am Heart Assoc; 2015 Jan; 4(1):e001521. PubMed ID: 25622599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-environment interactions of selected pharmacogenes in arterial hypertension.
    Bochud M; Guessous I
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):677-86. PubMed ID: 23234325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.
    Liljedahl U; Karlsson J; Melhus H; Kurland L; Lindersson M; Kahan T; Nyström F; Lind L; Syvänen AC
    Pharmacogenetics; 2003 Jan; 13(1):7-17. PubMed ID: 12544508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.
    Amaro-Álvarez L; Cordero-Ramos J; Calleja-Hernández MÁ
    Farm Hosp; 2024 Feb; ():. PubMed ID: 38341366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.